Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -1.35% | |
| Upper Bollinger Band Walk | Strength | -1.35% | |
| Wide Bands | Range Expansion | -1.35% | |
| Overbought Stochastic | Strength | -1.35% | |
| Upper Bollinger Band Touch | Strength | -1.35% | |
| Upper Bollinger Band Walk | Strength | -3.10% | |
| Wide Bands | Range Expansion | -3.10% | |
| Above Upper BB | Strength | -3.10% | |
| Overbought Stochastic | Strength | -3.10% | |
| Up 3 Days in a Row | Strength | -3.10% |
| Alert | Time |
|---|---|
| Possible NR7 | about 1 hour ago |
| Possible Inside Day | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Down 1% | about 2 hours ago |
| 1.5x Volume Pace | about 5 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/13/2024
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.19 |
| 52 Week Low | 1.05 |
| Average Volume | 256,445 |
| 200-Day Moving Average | 1.79 |
| 50-Day Moving Average | 1.78 |
| 20-Day Moving Average | 1.74 |
| 10-Day Moving Average | 1.99 |
| Average True Range | 0.20 |
| RSI (14) | 68.15 |
| ADX | 25.57 |
| +DI | 26.04 |
| -DI | 16.50 |
| Chandelier Exit (Long, 3 ATRs) | 1.74 |
| Chandelier Exit (Short, 3 ATRs) | 1.91 |
| Upper Bollinger Bands | 2.31 |
| Lower Bollinger Band | 1.18 |
| Percent B (%b) | 0.92 |
| BandWidth | 64.75 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.06 |
| MACD Histogram | 0.0753 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.52 | ||||
| Resistance 3 (R3) | 2.53 | 2.44 | 2.47 | ||
| Resistance 2 (R2) | 2.44 | 2.36 | 2.44 | 2.45 | |
| Resistance 1 (R1) | 2.33 | 2.32 | 2.29 | 2.32 | 2.44 |
| Pivot Point | 2.24 | 2.24 | 2.22 | 2.24 | 2.24 |
| Support 1 (S1) | 2.13 | 2.16 | 2.09 | 2.12 | 2.00 |
| Support 2 (S2) | 2.04 | 2.12 | 2.04 | 1.99 | |
| Support 3 (S3) | 1.93 | 2.04 | 1.97 | ||
| Support 4 (S4) | 1.92 |
